Ventyx Biosciences Inc (VTYX)
4.91
+0.23
(+4.91%)
USD |
NASDAQ |
May 02, 16:00
4.91
0.00 (0.00%)
After-Hours: 20:00
Ventyx Biosciences Total Liabilities (Quarterly): 33.77M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 33.77M |
| September 30, 2023 | 38.06M |
| June 30, 2023 | 20.96M |
| March 31, 2023 | 17.55M |
| December 31, 2022 | 17.50M |
| September 30, 2022 | 36.91M |
| Date | Value |
|---|---|
| June 30, 2022 | 19.03M |
| March 31, 2022 | 18.83M |
| December 31, 2021 | 12.28M |
| September 30, 2021 | 236.33M |
| June 30, 2021 | 181.78M |
| December 31, 2020 | 30.90M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
12.28M
Minimum
Dec 2021
236.33M
Maximum
Sep 2021
55.33M
Average
25.93M
Median
Total Liabilities (Quarterly) Benchmarks
| Anavex Life Sciences Corp | 12.50M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | 19.97M |
| Checkpoint Therapeutics Inc | 18.42M |
| RAPT Therapeutics Inc | 26.29M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 277.69M |
| Shareholders Equity (Quarterly) | 243.92M |